secwatch.observer — SEC 8-K summary
======================================

Issuer:     INOVIO PHARMACEUTICALS, INC. (INO)
CIK:        0001055726
Form:       8-K
Filed at:   2023-10-10T23:59:59+00:00
Accession:  0001193125-23-253450
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

INOVIO gets FDA nod to use Phase 1/2 data for INO-3107 BLA under accelerated approval; Phase 3 waived
--------------------------------------------------------------------------------

- FDA confirmed that completed Phase 1/2 trial data for INO-3107 in RRP can support BLA under accelerated approval; previously planned Phase 3 trial no longer required.
- Confirmatory trial must be initiated before BLA submission; design not yet finalized.
- If approved, INO-3107 would be first DNA medicine in the US and INOVIO's first commercial product.
- Phase 1/2 results: 81.3% (26/32) of patients had fewer surgical interventions; median reduction of 3 surgeries; strong T-cell immune response with durable memory.
- Cash runway guidance may change; company plans to provide updated cash guidance on Q3 2023 earnings call in November.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1055726/000119312523253450/0001193125-23-253450-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1055726/000119312523253450/d567242d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-253450

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer